I-O Biomarkers

Click a research area to learn more.

Immuno-Oncology
(I-O) biomarkers may be used to advance precision medicine

Bristol Myers Squibb is committed to investigating four key areas of I-O biomarker research.

Click on one of the biomarker categories to learn more.

Tumor Antigens

Tumor antigens are recognized as nonself or foreign by the host immune system.¹ They can initiate the adaptive immune response by priming the immune system.^1,2 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.

Learn about:

MSI-H/dMMR

Inflamed Tumor Markers

Inflamed tumors show evidence of immune-cell infiltration and activation in the tumor microenvironment.^3,4 Several Immuno-Oncology (I-O) biomarkers related to inflamed tumor markers are currently under investigation.

Learn about:

Inflammation Gene
Signature

PD-L1
TILs

Immune Suppression Markers

Cells and proteins within the tumor and its microenvironment can suppress T-cell activation, promote T-cell exhaustion, or activate regulatory T-cells.^5,6 Several exploratory
Immuno-Oncology (I-O) biomarkers are associated with inhibition of the antitumor response.

Learn about:

Select a biomarker

Tumor Antigens
Inflamed Tumor
Markers
Immune Suppression
Markers

Immuno-Oncology (I-O) biomarkers may be used to advance precision medicine

Bristol Myers Squibb is committed to investigating four key areas of I-O biomarker research. Tap on one of the biomarker categories to learn more.

Tumor antigens are recognized as nonself or foreign by the host immune system.¹ They can initiate the adaptive immune response by priming the immune system.^1,2 Several
Immuno-Oncology (I-O) biomarkers related to tumor antigens are currently under investigation.

Cells and proteins within the tumor and its microenvironment can suppress T-cell activation, promote T-cell exhaustion, or activate regulatory T-cells.^5,6 Several exploratory Immuno-Oncology (I-O) biomarkers are associated with inhibition of the antitumor response.

Many factors in the host envrionment may play a role in modulating an immune response. Outside of the tumor microenvironment, factors such as smoking, diet, UV exposure, infectious agents, and the gut microbiome can favorably or unfavorably affect the antitumor response.^7-9

Microbiome

Click the links below to navigate to the individual biomarker pages.

Tap the links below to navigate to the individual biomarker pages.

Tumor antigens

Inflamed tumor markers

Immune suppression markers

I-O biomarkers: Under investigation for their role in immuno-therapy

Learn more about where our I-O biomarker research is focused

Watch video

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about
our
current clinical trials

Learn more

REFERENCES–I-O Biomarkers

1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74. 2. Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456-465. 3. Masucci GV, Cesano A, Hawtin R, et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume 1 – pre-analytical and analytical validation. J Immunother Cancer.2016;4:76. 4. Hedge PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865-1874. 5. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138(2):105-115. 6. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875-7880. 7. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330. 8. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421. 9. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61.